Device Trial Radar · NCT04982588
Evolut PRO China Clinical Study
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Actual
Start
Jul 17, 2021
Primary completion
Mar 17, 2023
Study completion May 15, 2028
Sponsor
- Lead sponsor
- Medtronic CardiovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jul 29, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).
Conditions
- Severe, Symptomatic Aortic Stenosis
Interventions
Medtronic CoreValve™ Evolut™ PRO SystemDevice
The system comprised of the following three components: 1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV) 2. EnVeo™ PRO Delivery Catheter System (DCS) 3. EnVeo™ PRO Loading System (LS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause MortalityTime frame: 30 days
- Percentage (%) of Subjects With Evaluable Echocardiograms With Moderate or Severe Aortic Regurgitation by Transthoracic Echocardiography (TTE)Time frame: 30 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chinese PLA General Hospital, Chinese PLA Medical School
Beijing, Beijing Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.